Quantitative Neuromuscular Monitoring in Clinical Practice: A Professional Practice Change Initiative

Background: Residual neuromuscular blockade can be avoided with quantitative neuromuscular monitoring. The authors embarked on a professional practice initiative to attain documented train-of-four ratios greater than or equal to 0.90 in all patients for improved patient outcomes through reducing residual paralysis. Methods: The authors utilized equipment trials, educational videos, quantitative monitors in all anesthetizing locations, and electronic clinical decision support with real-time alerts, and initiated an ongoing professional practice metric. This was a retrospective assessment (2016 to 2020) of train-of-four ratios greater than or equal to 0.9 that were documented before extubation. Anesthesia records were manually reviewed for neuromuscular blockade management details. Medical charts of surgical patients who received a neuromuscular blocking drug were electronically searched for patient characteristics and outcomes. Results: From pre- to postimplementation, more patients were assigned American Society of Anesthesiologists Physical Status III to V, fewer were inpatients, the rocuronium average dose was higher, and more patients had a prereversal train-of-four count less than 4. Manually reviewed anesthesia records (n = 2,807) had 2 of 172 (1%) cases with documentation of train-of-four ratios greater than or equal to 0.90 in November 2016, which was fewer than the cases in December 2020 (250 of 269 [93%]). Postimplementation (February 1, 2020, to December 31, 2020), sugammadex (650 of 935 [70%]), neostigmine (195 of 935 [21%]), and no reversal (90 of 935 [10%]) were used to attain train-of-four ratios greater than or equal to 0.90 in 856 of 935 (92%) of patients. In the electronically searched medical charts (n = 20,181), postimplementation inpatients had shorter postanesthesia care unit lengths of stay (7% difference; median [in min] [25th, 75th interquartile range], 73 [55, 102] to 68 [49, 95]; P < 0.001), pulmonary complications were less (43% difference; 94 of 4,138 [2.3%] to 23 of 1,817 [1.3%]; P = 0.010; −1.0% difference [95% CI, –1.7 to –0.3%]), and hospital length of stay was shorter (median [in days] [25th, 75th], 3 [2, 5] to 2 [1, 4]; P < 0.001). Conclusions: In this professional practice initiative, documentation of train-of-four ratios greater than or equal to 0.90 occurred for 93% of patients in a busy clinical practice. Return-of-strength documentation is an intermediate outcome, and only one of many factors contributing to patient outcomes. A departmental professional practice initiative began with the goal of documenting a train-of-four ratio greater than or equal to 0.90 for all patients given a nondepolarizing neuromuscular blocking drug. This retrospective assessment of the implementation of documenting train-of-four ratios greater than or equal to 0.9 before extubation improved from 1% (2 of 172) of cases in November 2016 to 93% (250 of 269) of cases in December 2020. Attaining this endpoint required not only placing a quantitative monitor in each anesthetizing location but also ongoing educational efforts and follow-up.

[1]  R. Russell,et al.  Recommendations for standards of monitoring during anaesthesia and recovery 2021 , 2021, Anaesthesia.

[2]  J. Renew,et al.  Ease of Application of Various Neuromuscular Devices for Routine Monitoring , 2020, Anesthesia and analgesia.

[3]  Michaël Verdonck,et al.  Forty years of neuromuscular monitoring and postoperative residual curarisation: a meta-analysis and evaluation of confidence in network meta-analysis. , 2020, British journal of anaesthesia.

[4]  S. Brull,et al.  Epidemiology and outcomes of residual neuromuscular blockade: A systematic review of observational studies. , 2020, Journal of clinical anesthesia.

[5]  R. Soto,et al.  Sugammadex versus Neostigmine for Reversal of Neuromuscular Blockade and Postoperative Pulmonary Complications (STRONGER) , 2020, Anesthesiology.

[6]  J. Bourgain,et al.  Guidelines on muscle relaxants and reversal in anaesthesia adductor pollicis *, *. , 2020, Anaesthesia, critical care & pain medicine.

[7]  G. Murphy,et al.  Awake Volunteer Pain Scores During Neuromuscular Monitoring , 2020, Anesthesia and analgesia.

[8]  T. Takazawa,et al.  Comparison of incidence of anaphylaxis between sugammadex and neostigmine: a retrospective multicentre observational study. , 2019, British journal of anaesthesia.

[9]  M. Kurrek,et al.  Guidelines to the Practice of Anesthesia – Revised Edition 2020 , 2019, Canadian Journal of Anesthesia/Journal canadien d'anesthésie.

[10]  Shannon K. McWilliams,et al.  Neostigmine Versus Sugammadex for Reversal of Neuromuscular Blockade and Effects on Reintubation for Respiratory Failure or Newly Initiated Noninvasive Ventilation: An Interrupted Time Series Design , 2019, Anesthesia and analgesia.

[11]  B. Nair,et al.  A comparison of a prototype electromyograph vs. a mechanomyograph and an acceleromyograph for assessment of neuromuscular blockade† , 2019, Anaesthesia.

[12]  C. Lien,et al.  Heuristics, Overconfidence, and Experience: Impact on Monitoring Depth of Neuromuscular Blockade. , 2019, Anesthesia and analgesia.

[13]  H. Arkes,et al.  Anesthesiologists' Overconfidence in Their Perceived Knowledge of Neuromuscular Monitoring and Its Relevance to All Aspects of Medical Practice: An International Survey. , 2019, Anesthesia and analgesia.

[14]  M. Treggiari,et al.  Management of rocuronium neuromuscular block using a protocol for qualitative monitoring and reversal with neostigmine , 2018, British journal of anaesthesia.

[15]  H. Arkes,et al.  Consensus Statement on Perioperative Use of Neuromuscular Monitoring , 2017, Anesthesia and analgesia.

[16]  S. Lengyel,et al.  Impact of reversal strategies on the incidence of postoperative residual paralysis after rocuronium relaxation without neuromuscular monitoring: A partially randomised placebo controlled trial , 2017, European journal of anaesthesiology.

[17]  S. Lengyel,et al.  Reversal of Vecuronium-induced Neuromuscular Blockade with Low-dose Sugammadex at Train-of-four Count of Four: A Randomized Controlled Trial , 2017, Anesthesiology.

[18]  M. R. Gätke,et al.  Objective neuromuscular monitoring of neuromuscular blockade in Denmark: an online‐based survey of current practice , 2017, Acta anaesthesiologica Scandinavica.

[19]  Jesse M. Ehrenfeld,et al.  Nondepolarizing Neuromuscular Blocking Agents, Reversal, and Risk of Postoperative Pneumonia , 2016, Anesthesiology.

[20]  Torin D. Shear,et al.  Residual Neuromuscular Block in the Elderly: Incidence and Clinical Implications , 2015, Anesthesiology.

[21]  B. Hindman,et al.  The Implementation of Quantitative Electromyographic Neuromuscular Monitoring in an Academic Anesthesia Department: Follow-Up Observations. , 2015, Anesthesia and analgesia.

[22]  A. Galarneau,et al.  The RECITE Study: A Canadian Prospective, Multicenter Study of the Incidence and Severity of Residual Neuromuscular Blockade , 2015, Anesthesia and analgesia.

[23]  T. Kurth,et al.  Dose-dependent Association between Intermediate-acting Neuromuscular-blocking Agents and Postoperative Respiratory Complications , 2015, Anesthesiology.

[24]  M. Eikermann,et al.  Effects of Neostigmine Reversal of Nondepolarizing Neuromuscular Blocking Agents on Postoperative Respiratory Outcomes: A Prospective Study , 2014, Anesthesiology.

[25]  B. Hindman,et al.  The Implementation of Quantitative Electromyographic Neuromuscular Monitoring in an Academic Anesthesia Department , 2014, Anesthesia and analgesia.

[26]  S. Phillips,et al.  An Ipsilateral Comparison of Acceleromyography and Electromyography During Recovery from Nondepolarizing Neuromuscular Block Under General Anesthesia in Humans , 2013, Anesthesia and analgesia.

[27]  M. Ozaki,et al.  Reversal with Sugammadex in the Absence of Monitoring Did Not Preclude Residual Neuromuscular Block , 2013, Anesthesia and analgesia.

[28]  F. Abelha,et al.  Residual neuromuscular block as a risk factor for critical respiratory events in the post anesthesia care unit. , 2013, Revista espanola de anestesiologia y reanimacion.

[29]  Jesse M. Ehrenfeld,et al.  Intermediate acting non-depolarizing neuromuscular blocking agents and risk of postoperative respiratory complications: prospective propensity score matched cohort study , 2012, BMJ : British Medical Journal.

[30]  J. Vender,et al.  Intraoperative Acceleromyography Monitoring Reduces Symptoms of Muscle Weakness and Improves Quality of Recovery in the Early Postoperative Period , 2011, Anesthesiology.

[31]  J. Vieira,et al.  What Rules of Thumb Do Clinicians Use to Decide Whether to Antagonize Nondepolarizing Neuromuscular Blocking Drugs? , 2011, Anesthesia and analgesia.

[32]  Jesse M. Ehrenfeld,et al.  Using real-time clinical decision support to improve performance on perioperative quality and process measures. , 2011, Anesthesiology clinics.

[33]  W. Sandberg,et al.  Postoperative residual curarization from intermediate-acting neuromuscular blocking agents delays recovery room discharge. , 2010, British journal of anaesthesia.

[34]  S. Brull,et al.  Residual Neuromuscular Block: Lessons Unlearned. Part II Methods to Reduce the Risk of Residual Weakness , 2010, Anesthesia and analgesia.

[35]  S. Brull,et al.  A Survey of Current Management of Neuromuscular Block in the United States and Europe , 2010, Anesthesia and analgesia.

[36]  B. Plaud,et al.  Residual Paralysis after Emergence from Anesthesia , 2010, Anesthesiology.

[37]  J. Hannam,et al.  Incidence of Residual Neuromuscular Blockade in a Post-Anaesthetic Care Unit , 2010, Anaesthesia and intensive care.

[38]  J. Vender,et al.  Residual Neuromuscular Blockade and Critical Respiratory Events in the Postanesthesia Care Unit , 2008, Anesthesia and analgesia.

[39]  J. Viby-Mogensen,et al.  Acceleromyography for Use in Scientific and Clinical Practice: A Systematic Review of the Evidence , 2008, Anesthesiology.

[40]  Florian Vogt,et al.  The predisposition to inspiratory upper airway collapse during partial neuromuscular blockade. , 2007, American journal of respiratory and critical care medicine.

[41]  J. Vender,et al.  Residual Paralysis at the Time of Tracheal Extubation , 2005, Anesthesia and analgesia.

[42]  B. Plaud,et al.  Residual Paralysis in the PACU after a Single Intubating Dose of Nondepolarizing Muscle Relaxant with an Intermediate Duration of Action , 2003, Anesthesiology.

[43]  J. Dillon,et al.  Recurarization--fact or fiction. , 1971, Anesthesia and Analgesia.